AKT1 and non-small cell lung carcinoma: Th22 cells and its special cytokine IL-22 accelerate tumor progression and impair the prognosis of patients with NSCLC by antagonizing the apoptosis-inducing and cell cycle-arresting effect of antitumor drugs, promoting tumor cell migration and tumor tissue growth, and activating the JAK-STAT3/MAPK/AKT signaling pathway.